Lydia Mok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lydia Mok has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Taesung Park
Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea
3 shared publications - Vanessa D. Jonsson
University of California, Santa Cruz
3 shared publications - Nicholas R Rose
University of California, Santa Cruz
2 shared publications - Alessandra Rodriguez Y Baena
University of California, Santa Cruz
1 shared publication - Andrew Robinson
University of California, Santa Cruz
1 shared publication - Angela Deguzman
University of California, Santa Cruz
1 shared publication
Latest Publications
- Open Access
PRISM : Peptide-specificity annotation of T-cell receptors with uncertainty quantification
Mapping T-cell receptor (TCR) sequences to their cognate peptide-major histocompatibility complex (pMHC) ligands underlies both basic immunology and T-cell target discovery, yet current models aimed at predicting TCR specificity are limited by sparse labels, viral-biased training data, and an inability to recognize receptors outside their training distribution. We present PRISM, an uncertainty-aware metric-learning framework for TCRβ sequence representation. PRISM embeds receptors into a peptide-organized latent space, returns top-k peptides by nearest-neighbor retrieval, and abstains on out-of-distribution receptors by modeling an intrinsic uncertainty that tracks annotation correctness. To offset the viral bias of public databases, PRISM augments training data with structure-guided synthetic receptors that diversify TCR sequences while preserving the energetics of the TCR-pMHC interface. Across a held-out set of 923 peptides and the independent IMMREP23 benchmark, PRISM matches or exceeds sequence-based models, with largest gains on rare epitopes. Finally, PRISM learns attention weights on TCR residues that concentrate on the CDR3β salt-bridge and hydrophobic contacts central to peptide recognition, linking PRISM's positional focus to the biochemical properties of TCR-pMHC structures.
Open AccessPRISM : Peptide-specificity annotation of T-cell receptors with uncertainty quantification
Mapping T-cell receptor (TCR) sequences to their cognate peptide-major histocompatibility complex (pMHC) ligands underlies both basic immunology and T-cell target discovery, yet current models aimed at predicting TCR specificity are limited by sparse labels, viral-biased training data, and an inability to recognize receptors outside their training distribution. We present PRISM, an uncertainty-aware metric-learning framework for TCRβ sequence representation. PRISM embeds receptors into a peptide-organized latent space, returns top-k peptides by nearest-neighbor retrieval, and abstains on out-of-distribution receptors by modeling an intrinsic uncertainty that tracks annotation correctness. To offset the viral bias of public databases, PRISM augments training data with structure-guided synthetic receptors that diversify TCR sequences while preserving the energetics of the TCR-pMHC interface. Across a held-out set of 923 peptides and the independent IMMREP23 benchmark, PRISM matches or exceeds sequence-based models, with largest gains on rare epitopes. Finally, PRISM learns attention weights on TCR residues that concentrate on the CDR3β salt-bridge and hydrophobic contacts central to peptide recognition, linking PRISM's positional focus to the biochemical properties of TCR-pMHC structures.
- Open Access
TRIOPS: A deep learning framework for prediction of T cell receptor-MHC binding specificity
T cell receptor (TCR) recognition is MHC-restricted, yet accurately predicting a TCR's restricting HLA allele remains an open problem. We present TRIOPS, a dual-branch convolutional model with soft cross-attention that predicts TCR-MHC restriction from amino acid sequence alone. TRIOPS uses cross-reactivity-aware negative sampling by HLA pseudosequence similarity to reduce allele-boundary label noise, extending prediction to alleles absent from training. TRIOPS reaches a held-out AUC of 0.97 for paired TCR; and 0.92 for TCR-only inputs, generalizes to unseen receptors and HLA alleles, and after locus-specific calibration, assigns TCR clonotypes to their likeliest restricting allele across an individual's HLA genotype. In TCGA tumors, TCR repertoires preferentially engage the expression-lost allele at HLA-A and HLA-B and the retained allele at HLA-C, recapitulating from bulk tumor RNA-seq the allele specific HLA loss previously linked to immune escape.
Open AccessTRIOPS: A deep learning framework for prediction of T cell receptor-MHC binding specificity
T cell receptor (TCR) recognition is MHC-restricted, yet accurately predicting a TCR's restricting HLA allele remains an open problem. We present TRIOPS, a dual-branch convolutional model with soft cross-attention that predicts TCR-MHC restriction from amino acid sequence alone. TRIOPS uses cross-reactivity-aware negative sampling by HLA pseudosequence similarity to reduce allele-boundary label noise, extending prediction to alleles absent from training. TRIOPS reaches a held-out AUC of 0.97 for paired TCR; and 0.92 for TCR-only inputs, generalizes to unseen receptors and HLA alleles, and after locus-specific calibration, assigns TCR clonotypes to their likeliest restricting allele across an individual's HLA genotype. In TCGA tumors, TCR repertoires preferentially engage the expression-lost allele at HLA-A and HLA-B and the retained allele at HLA-C, recapitulating from bulk tumor RNA-seq the allele specific HLA loss previously linked to immune escape.
- Open Access
A rare HSC-derived megakaryocyte progenitor accumulates via enhanced survival and contributes to exacerbated thrombopoiesis upon aging
Distinct routes of cellular production from hematopoietic stem cells (HSCs) have defined our current view of hematopoiesis. Recently, we challenged classical views of platelet generation, demonstrating that megakaryocyte progenitors (MkPs), and ultimately platelets, can be specified via an alternate and additive route of HSC-direct specification specifically during aging. This “shortcut” pathway generates hyperactive platelets likely to contribute to age-related platelet-mediated morbidities. Here, we used single-cell RNA/CITEseq to demonstrate that these age-unique, non-canonical (nc)MkPs can be prospectively defined and experimentally isolated from wild type mice. Surprisingly, this revealed that a rare population of ncMkPs also exist in young mice. Young and aged ncMkPs are functionally distinct from their canonical (c)MkP counterparts, with aged ncMkPs paradoxically and uniquely exhibiting enhanced survival and platelet generation capacity. We further demonstrate that aged HSCs generate significantly more ncMkPs than their younger counterparts, yet this is accomplished without strict clonal restriction. Together, these findings reveal significant phenotypic, functional, and aging-dependent heterogeneity among the MkP pool and uncover unique features of megakaryopoiesis throughout life, potentially offering cellular and molecular targets for mitigation of age-related adverse thrombotic events.
Open AccessA rare HSC-derived megakaryocyte progenitor accumulates via enhanced survival and contributes to exacerbated thrombopoiesis upon aging
Distinct routes of cellular production from hematopoietic stem cells (HSCs) have defined our current view of hematopoiesis. Recently, we challenged classical views of platelet generation, demonstrating that megakaryocyte progenitors (MkPs), and ultimately platelets, can be specified via an alternate and additive route of HSC-direct specification specifically during aging. This “shortcut” pathway generates hyperactive platelets likely to contribute to age-related platelet-mediated morbidities. Here, we used single-cell RNA/CITEseq to demonstrate that these age-unique, non-canonical (nc)MkPs can be prospectively defined and experimentally isolated from wild type mice. Surprisingly, this revealed that a rare population of ncMkPs also exist in young mice. Young and aged ncMkPs are functionally distinct from their canonical (c)MkP counterparts, with aged ncMkPs paradoxically and uniquely exhibiting enhanced survival and platelet generation capacity. We further demonstrate that aged HSCs generate significantly more ncMkPs than their younger counterparts, yet this is accomplished without strict clonal restriction. Together, these findings reveal significant phenotypic, functional, and aging-dependent heterogeneity among the MkP pool and uncover unique features of megakaryopoiesis throughout life, potentially offering cellular and molecular targets for mitigation of age-related adverse thrombotic events.
- Open Access
- 15 November 2021
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 15 (6) , 912-921
Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)
Jae Seung Kang, Lydia Mok, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Yoo-Seok Yoon, Ho-Seong Han, Dae Wook Hwang, Jae Hoon Lee, Woo Jung Lee, Sang Jae Park, Joon Seong Park, Yonghoon Kim, Huisong Lee, Young-Dong Yu, Jae Do Yang, Seung Eun Lee, Il Young Park, Chi-Young Jeong, Younghoon Roh, Seong-Ryong Kim, Ju Ik Moon, Sang Kuon Lee, Hee Joon Kim, Seungyeoun Lee, Hongbeom Kim, Wooil Kwon, Chang-Sup Lim, Jin-Young Jang, and Taesung Park. Gut and Liver 2021;15:912-21. https://doi.org/10.5009/gnl20306
- 15 November 2021
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 15 (6) , 912-921
Open AccessDevelopment and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)
Jae Seung Kang, Lydia Mok, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Yoo-Seok Yoon, Ho-Seong Han, Dae Wook Hwang, Jae Hoon Lee, Woo Jung Lee, Sang Jae Park, Joon Seong Park, Yonghoon Kim, Huisong Lee, Young-Dong Yu, Jae Do Yang, Seung Eun Lee, Il Young Park, Chi-Young Jeong, Younghoon Roh, Seong-Ryong Kim, Ju Ik Moon, Sang Kuon Lee, Hee Joon Kim, Seungyeoun Lee, Hongbeom Kim, Wooil Kwon, Chang-Sup Lim, Jin-Young Jang, and Taesung Park. Gut and Liver 2021;15:912-21. https://doi.org/10.5009/gnl20306
- Open Access
- 31 December 2019
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 17 (4) , e45
HisCoM-PAGE: software for hierarchical structural component models for pathway analysis of gene expression data
To identify pathways associated with survival phenotypes using gene expression data, we recently proposed the hierarchical structural component model for pathway analysis of gene expression data (HisCoM-PAGE) method. The HisCoM-PAGE software can consider hierarchical structural relationships between genes and pathways and analyze multiple pathways simultaneously. It can be applied to various types of gene expression data, such as microarray data or RNA sequencing data. We expect that the HisCoM-PAGE software will make our method more easily accessible to researchers who want to perform pathway analysis for survival times.
- 31 December 2019
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 17 (4) , e45
Open AccessHisCoM-PAGE: software for hierarchical structural component models for pathway analysis of gene expression data
To identify pathways associated with survival phenotypes using gene expression data, we recently proposed the hierarchical structural component model for pathway analysis of gene expression data (HisCoM-PAGE) method. The HisCoM-PAGE software can consider hierarchical structural relationships between genes and pathways and analyze multiple pathways simultaneously. It can be applied to various types of gene expression data, such as microarray data or RNA sequencing data. We expect that the HisCoM-PAGE software will make our method more easily accessible to researchers who want to perform pathway analysis for survival times.
- Open Access
- 31 December 2018
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 16 (4) , e32
Ovarian Cancer Prognostic Prediction Model Using RNA Sequencing Data
Ovarian cancer is one of the leading causes of cancer-related deaths in gynecologic malignancies. Over 70 % of ovarian cancer cases are high-grade serous ovarian cancers (HGSC) and have high death rates due to their resistance to chemotherapy. Despite advances in surgical and pharmaceutical therapies, overall survival rates are not good and accurate prediction of prognosis is not easy because of the highly heterogeneous nature of ovarian cancer. To improve patient's prognosis through proper treatment, we present a prognostic prediction model by integrating the high dimensional RNA sequencing data with their clinical data through the following steps: (1) gene filtration, (2) pre-screening, (3) gene marker selection (4) integrated study of selected gene markers and prediction model building. These steps of the prognostic prediction model can be applied to other types of cancer besides ovarian cancer.
- 31 December 2018
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 16 (4) , e32
Open AccessOvarian Cancer Prognostic Prediction Model Using RNA Sequencing Data
Ovarian cancer is one of the leading causes of cancer-related deaths in gynecologic malignancies. Over 70 % of ovarian cancer cases are high-grade serous ovarian cancers (HGSC) and have high death rates due to their resistance to chemotherapy. Despite advances in surgical and pharmaceutical therapies, overall survival rates are not good and accurate prediction of prognosis is not easy because of the highly heterogeneous nature of ovarian cancer. To improve patient's prognosis through proper treatment, we present a prognostic prediction model by integrating the high dimensional RNA sequencing data with their clinical data through the following steps: (1) gene filtration, (2) pre-screening, (3) gene marker selection (4) integrated study of selected gene markers and prediction model building. These steps of the prognostic prediction model can be applied to other types of cancer besides ovarian cancer.